Compare LEDS & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEDS | ERNA |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 10.0M |
| IPO Year | 2010 | N/A |
| Metric | LEDS | ERNA |
|---|---|---|
| Price | $1.58 | $0.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.7K | ★ 72.0K |
| Earning Date | 01-14-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $44,317,000.00 | $1,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 824.43 | N/A |
| 52 Week Low | $1.41 | $0.67 |
| 52 Week High | $3.37 | $5.55 |
| Indicator | LEDS | ERNA |
|---|---|---|
| Relative Strength Index (RSI) | 35.20 | 24.09 |
| Support Level | $1.51 | $1.12 |
| Resistance Level | $1.79 | $1.28 |
| Average True Range (ATR) | 0.10 | 0.11 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 15.68 | 0.00 |
SemiLEDs Corp develops, manufactures, and sells light-emitting diode chips and LED components. The company's products include LED Chips, LED Components, and Lighting Products. Its products are used for general lighting applications, including street lights and commercial, industrial, system, and residential lighting; specialty industrial applications, such as ultraviolet, or Ultraviolet, curing of polymers, LED light therapy in medical/cosmetic applications, counterfeit detection, LED lighting for horticulture applications, architectural lighting and entertainment lighting. Substantial revenue is generated from the sale of LED components products. Geographically, it derives a majority of its revenue from Japan.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.